Dasatinib

Definition

An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with a variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.

Also known as 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate, BMS 354825, BMS-354825, BMS354825, DASATINIB, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel — per NCIT

Also identified as

• ATC L01EA02 per RXNORM
• NCIT NCIT:C38713 per NCIT
• SCTID 422756008 per RXNORM
• SCTID 423658008 per RXNORM
• UNII RBZ1571X5H per RXNORM

Indications

Organ Effects

2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.